PURPOSE: CYP3A4 and P-glycoprotein (P-gp) are present in the human intestine and mediate intestinal first-pass metabolism and the efflux of oral drugs, respectively. We aimed to predict whether intestinal CYP3A4/P-gp is saturated in a therapeutic dose range. METHODS: Information on the Michaelis-Menten constant (Km), product of the fraction absorbed (Fa) and intestinal availability (Fg) (FaFg) of CYP3A4/P-gp substrates, and clinical AUC data including two or more different dosages for each CYP3A4/P-gp substrate was collected. The relationship between dose-normalized AUC and dose/Km value, termed the linearity index (LIN), was analyzed. RESULTS: Among 38 CYP3A4 and/or P-gp substrates, 16 substrates exhibited nonlinear pharmacokinetics and 22 substrates exhibited linear pharmacokinetics. Substrates with a small LIN tended to exhibit linear pharmacokinetics. The smallest LIN values of a substrate that exhibited nonlinear pharmacokinetics were 2.8 and 0.77 L for CYP3A4 and P-gp substrates, respectively. A decision tree for predicting nonlinear pharmacokinetics of CYP3A4/P-gp substrates based on LIN and FaFg of drugs was proposed. This decision tree correctly predicted linearity or nonlinearity for 24 of 29 drugs. CONCLUSIONS: LIN is useful for predicting CYP3A4/P-gp-mediated nonlinearity in intestinal absorption process in humans.
PURPOSE:CYP3A4 and P-glycoprotein (P-gp) are present in the human intestine and mediate intestinal first-pass metabolism and the efflux of oral drugs, respectively. We aimed to predict whether intestinal CYP3A4/P-gp is saturated in a therapeutic dose range. METHODS: Information on the Michaelis-Menten constant (Km), product of the fraction absorbed (Fa) and intestinal availability (Fg) (FaFg) of CYP3A4/P-gp substrates, and clinical AUC data including two or more different dosages for each CYP3A4/P-gp substrate was collected. The relationship between dose-normalized AUC and dose/Km value, termed the linearity index (LIN), was analyzed. RESULTS: Among 38 CYP3A4 and/or P-gp substrates, 16 substrates exhibited nonlinear pharmacokinetics and 22 substrates exhibited linear pharmacokinetics. Substrates with a small LIN tended to exhibit linear pharmacokinetics. The smallest LIN values of a substrate that exhibited nonlinear pharmacokinetics were 2.8 and 0.77 L for CYP3A4 and P-gp substrates, respectively. A decision tree for predicting nonlinear pharmacokinetics of CYP3A4/P-gp substrates based on LIN and FaFg of drugs was proposed. This decision tree correctly predicted linearity or nonlinearity for 24 of 29 drugs. CONCLUSIONS: LIN is useful for predicting CYP3A4/P-gp-mediated nonlinearity in intestinal absorption process in humans.
Authors: Jane L Wang; Karl Aston; David Limburg; Cindy Ludwig; Ann E Hallinan; Francis Koszyk; Bruce Hamper; David Brown; Matthew Graneto; John Talley; Timothy Maziasz; Jaime Masferrer; Jeffery Carter Journal: Bioorg Med Chem Lett Date: 2010-07-23 Impact factor: 2.823
Authors: Xiao-Jian Zhou; R Colin Garner; Sheila Nicholson; C James Kissling; Douglas Mayers Journal: J Clin Pharmacol Date: 2009-09-23 Impact factor: 3.126
Authors: Jari J Lilja; Janne T Backman; Jouko Laitila; Harri Luurila; Pertti J Neuvonen Journal: Clin Pharmacol Ther Date: 2003-03 Impact factor: 6.875
Authors: Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin Journal: Drug Metab Dispos Date: 2006-02-07 Impact factor: 3.922
Authors: Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2015-03-23 Impact factor: 5.191
Authors: Ayman F El-Kattan; Manthena V Varma; Stefan J Steyn; Dennis O Scott; Tristan S Maurer; Arthur Bergman Journal: Pharm Res Date: 2016-09-12 Impact factor: 4.200